Press releases
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
As of last trade Organon & Co (1OGN:MIL) traded at 19.89, -1.29% below its 52-week high of 20.15, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.89 |
---|---|
High | 19.89 |
Low | 19.89 |
Bid | 18.96 |
Offer | 19.53 |
Previous close | 19.37 |
Average volume | 38.25 |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.15 |
Market cap | 5.40bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 5.35% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of May 17 2024 16:25 BST.
More ▼